Akeso's first overall survival readout for its Keytruda challenger caused a violent market reaction. AstraZeneca disclosed ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. $350M ...

Hiroyuki Okuzawa, CEO of Japanese pharmaceutical giant Daiichi Sankyo, talks about the company's revenue driver in its latest report, and the lack of visibility from the impact of potential U.S.

Look, if there’s one Predator movie I’m begging for, it’s the one where Hiroyuki Sanada goes full samurai on an alien in Edo-era Japan. And it could happen. But there’s a catch: Dan Trachtenberg isn’t ...